Angiopoietin-2 and the Vascular Endothelial Growth Factor Promote Migration and Invasion in Hepatocellular Carcinoma- and Intrahepatic Cholangiocarcinoma-Derived Spheroids

Aggressive hepatocellular carcinoma (HCC) overexpressing Angiopoietin-2 (ANG-2) (a protein linked with angiogenesis, proliferation, and epithelial–mesenchymal transition (EMT)), shares 95% of up-regulated genes and a similar poor prognosis with the proliferative subgroup of intrahepatic cholangiocarcinoma (iCCA). We analyzed the pro-invasive effect of ANG-2 and its regulator vascular endothelial growth factor (VEGF) on HCC and CCA spheroids to uncover posUsible common ways of response. Four cell lines were used: Hep3B and HepG2 (HCC), HuCC-T1 (iCCA), and EGI-1 (extrahepatic CCA). We treated the spheroids with recombinant human (rh) ANG-2 and/or VEGF and then observed the changes at the baseline, after 24 h, and again after 48 h. Proangiogenic stimuli increased migration and invasion capability in HCC- and iCCA-derived spheroids and were associated with a modification in EMT phenotypic markers (a decrease in E-cadherin and an increase in N-cadherin and Vimentin), especially at the migration front. Inhibitors targeting ANG-2 (Trebananib) and the VEGF (Bevacizumab) effectively blocked the migration ability of spheroids that had been stimulated with rh-ANG-2 and rh-VEGF. Overall, our findings highlight the critical role played by ANG-2 and the VEGF in enhancing the ability of HCC- and iCCA-derived spheroids to migrate and invade, which are key processes in cancer progression.

[1]  A. Jalil,et al.  Harnessing function of EMT in hepatocellular carcinoma: From biological view to nanotechnological standpoint. , 2023, Environmental research.

[2]  S. Kaur,et al.  VEGF-mediated tumour growth and EMT in 2D and 3D cell culture models of hepatocellular carcinoma , 2022, Oncology letters.

[3]  R. Braren,et al.  Angpt2/Tie2 autostimulatory loop controls tumorigenesis , 2022, EMBO molecular medicine.

[4]  Ai-ni Chen,et al.  The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis , 2022, World Journal of Surgical Oncology.

[5]  G. Berx,et al.  Partial EMT takes the lead in cancer metastasis. , 2021, Developmental cell.

[6]  G. Christofori,et al.  Distinct contributions of partial and full EMT to breast cancer malignancy. , 2021, Developmental cell.

[7]  C. Dehelean,et al.  Experimental Models of Hepatocellular Carcinoma—A Preclinical Perspective , 2021, Cancers.

[8]  Chengcheng Liao,et al.  Partial EMT in Squamous Cell Carcinoma: A Snapshot , 2021, International journal of biological sciences.

[9]  N. Khuntikeo,et al.  Establishment of a Potential Serum Biomarker Panel for the Diagnosis and Prognosis of Cholangiocarcinoma Using Decision Tree Algorithms , 2021, Diagnostics.

[10]  Z. Abdolmaleki,et al.  Bevacizumab regulates inflammatory cytokines and inhibits VEGFR2 signaling pathway in an ovalbumin-induced rat model of airway hypersensitivity , 2021, Inflammopharmacology.

[11]  F. Ning,et al.  Angiopoietin 2 stimulates trophoblast invasion via a mechanism associated with JNK signaling. , 2021, Molecular human reproduction.

[12]  Ana C. Henriques,et al.  Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research , 2020, Pharmaceutics.

[13]  H. Vlierberghe,et al.  The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma , 2020, Cells.

[14]  B. Goeppert,et al.  RNA Sequencing of Hepatobiliary Cancer Cell Lines: Data and Applications to Mutational and Transcriptomic Profiling , 2020, Cancers.

[15]  D. Ribatti,et al.  Epithelial-Mesenchymal Transition in Cancer: A Historical Overview , 2020, Translational oncology.

[16]  B. Carr,et al.  Inflammatory Mechanisms of HCC Development , 2020, Cancers.

[17]  R. Kelley,et al.  Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response , 2019, Journal of Immunotherapy for Cancer.

[18]  M. S. Sajib,et al.  Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology , 2019, Cells.

[19]  Manping Huang,et al.  Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell , 2018, BMC Gastroenterology.

[20]  R. Finn,et al.  The Role of Angiogenesis in Hepatocellular Carcinoma , 2018, Clinical Cancer Research.

[21]  M. Saitoh Involvement of partial EMT in cancer progression. , 2018, Journal of biochemistry.

[22]  Kuen-Feng Chen,et al.  Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response. , 2018, European journal of cancer.

[23]  F. Bosch-Morell,et al.  Bevacizumab Diminishes Inflammation in an Acute Endotoxin-Induced Uveitis Model , 2018, Front. Pharmacol..

[24]  V. Mittal Epithelial Mesenchymal Transition in Tumor Metastasis. , 2018, Annual review of pathology.

[25]  Z. Dong,et al.  Ang-2 promotes lung cancer metastasis by increasing epithelial-mesenchymal transition , 2018, Oncotarget.

[26]  H. Han,et al.  VEGF Overexpression Predicts Poor Survival in Hepatocellular Carcinoma , 2017, Open medicine.

[27]  M. Grinstaff,et al.  Embedded Spheroids as Models of the Cancer Microenvironment , 2017, Advanced biosystems.

[28]  S. Okada,et al.  Activation of Vimentin Is Critical to Promote a Metastatic Potential of Cholangiocarcinoma Cells. , 2017, Oncology research.

[29]  Yanming Zhou,et al.  Survival after surgical resection of distal cholangiocarcinoma: A systematic review and meta-analysis of prognostic factors. , 2017, Asian journal of surgery.

[30]  V. Paradis,et al.  Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks. , 2017, Journal of hepatology.

[31]  Vítor M Gaspar,et al.  3D tumor spheroids: an overview on the tools and techniques used for their analysis. , 2016, Biotechnology advances.

[32]  A. Chakraborti,et al.  Vascular endothelial growth factor: Evidence for autocrine signaling in hepatocellular carcinoma cell lines affecting invasion. , 2016, Indian journal of cancer.

[33]  Petra Koudelkova,et al.  Role of epithelial to mesenchymal transition in hepatocellular carcinoma. , 2016, Journal of hepatology.

[34]  J. Kim,et al.  Angiopoietin-2 promotes ER+ breast cancer cell survival in bone marrow niche , 2016, Endocrine-related cancer.

[35]  Ning Zhang,et al.  Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma , 2016, Oncotarget.

[36]  Gianluigi Giannelli,et al.  Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study , 2015, Gut.

[37]  L. weiswald,et al.  Spherical Cancer Models in Tumor Biology1 , 2015, Neoplasia.

[38]  R. Lencioni,et al.  Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma , 2014, Hepatology.

[39]  Hyung-chan Kim,et al.  Gln-362 of Angiopoietin-2 Mediates Migration of Tumor and Endothelial Cells through Association with α5β1 Integrin , 2014, The Journal of Biological Chemistry.

[40]  T. Meshel,et al.  Inflammatory factors of the tumor microenvironment induce plasticity in nontransformed breast epithelial cells: EMT, invasion, and collapse of normally organized breast textures. , 2013, Neoplasia.

[41]  Jian Li,et al.  Differential Expression of Fascin, E-cadherin and Vimentin: Proteins Associated With Survival of Cholangiocarcinoma Patients , 2013, The American journal of the medical sciences.

[42]  P. Saharinen,et al.  Angiopoietin signaling in the vasculature. , 2013, Experimental cell research.

[43]  R. Beroukhim,et al.  Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. , 2013, Gastroenterology.

[44]  Aiju Fang,et al.  Expression and prognostic significance of vascular endothelial growth factor receptor 1 in hepatocellular carcinoma , 2012, Journal of Clinical Pathology.

[45]  Li Zhang,et al.  VEGF is essential for the growth and migration of human hepatocellular carcinoma cells , 2012, Molecular Biology Reports.

[46]  M. Rugge,et al.  Nuclear expression of S100A4 calcium‐binding protein increases cholangiocarcinoma invasiveness and metastasization , 2011, Hepatology.

[47]  N. Ferrara,et al.  Autocrine VEGF Signaling Synergizes with EGFR in Tumor Cells to Promote Epithelial Cancer Development , 2010, Cell.

[48]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[49]  A. Ryan,et al.  Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines , 2009, Molecular Cancer Therapeutics.

[50]  Derek Y. Chiang,et al.  Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. , 2009, Cancer research.

[51]  M. Chopp,et al.  Angiopoietin 2 Mediates the Differentiation and Migration of Neural Progenitor Cells in the Subventricular Zone after Stroke* , 2009, The Journal of Biological Chemistry.

[52]  D. Jeoung,et al.  CAGE, a cancer/testis antigen, induces c-FLIPL and Snail to enhance cell motility and increase resistance to an anti-cancer drug , 2009, Biotechnology Letters.

[53]  U. Schmidt-Erfurth,et al.  Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin) , 2008, British Journal of Ophthalmology.

[54]  Asif Ahmed,et al.  VEGF Induces Tie2 Shedding via a Phosphoinositide 3-Kinase/Akt–Dependent Pathway to Modulate Tie2 Signaling , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[55]  M. J. Jarzynka,et al.  Angiopoietin-2 Stimulates Breast Cancer Metastasis through the α5β1 Integrin-Mediated Pathway , 2007 .

[56]  D. Schuppan,et al.  Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. , 2007, Biochemical pharmacology.

[57]  G. Thurston,et al.  Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting , 2007, Proceedings of the National Academy of Sciences.

[58]  S. Choi,et al.  Comparison of Combined Hepatocellular and Cholangiocarcinoma with Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma , 2006, Surgery Today.

[59]  L. Fu,et al.  Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma. , 2006, Journal of experimental & clinical cancer research : CR.

[60]  Zhi-su Liu,et al.  Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. , 2006, World journal of gastroenterology.

[61]  L. Meng,et al.  Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2. , 2006, Oncology reports.

[62]  D. Schlaepfer,et al.  Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway. , 2006, Cancer research.

[63]  H. Yoshiji,et al.  Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice , 2005, Gut.

[64]  L. Ellis,et al.  Vascular endothelial growth factor receptor‐1 promotes migration and invasion in pancreatic carcinoma cell lines , 2005, Cancer.

[65]  Yiqian Zhu,et al.  Angiopoietin-2 Facilitates Vascular Endothelial Growth Factor-Induced Angiogenesis in the Mature Mouse Brain , 2005, Stroke.

[66]  Lee M Ellis,et al.  Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells , 2005, Oncogene.

[67]  J. Llovet,et al.  Updated treatment approach to hepatocellular carcinoma , 2005, Journal of Gastroenterology.

[68]  P. Kristjansen,et al.  Angiogenic synergy of bFGF and VEGF is antagonized by Angiopoietin-2 in a modified in vivo Matrigel assay. , 2004, Microvascular research.

[69]  G. Thurston Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis , 2003, Cell and Tissue Research.

[70]  N. Yang,et al.  The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. , 2003, Cancer research.

[71]  K. Alitalo,et al.  Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[72]  H. Yu,et al.  Overexpression of VEGF and Angiopoietin 2: A Key to High Vascularity of Hepatocellular Carcinoma? , 2003, Modern Pathology.

[73]  C. Shou,et al.  Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells. , 2002, World journal of gastroenterology.

[74]  B. Davidson,et al.  Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-XL and Mcl-1 expressing human cholangiocarcinoma cells , 2002, Gut.

[75]  K. Sugimachi,et al.  Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma , 2002, Hepatology.

[76]  S. Jiang,et al.  Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[77]  I. Stamenkovic,et al.  Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. , 2001, The American journal of pathology.

[78]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[79]  M. El-Sabban,et al.  Bevacizumab induces inflammation in MDA-MB-231 breast cancer cell line and in a mouse model. , 2019, Cellular signalling.

[80]  Linhong Deng,et al.  Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B , 2014, Cytotechnology.

[81]  G. Christofori,et al.  Angiopoietins in angiogenesis. , 2013, Cancer letters.